GDF11 against aging

Harvard University spinout Elevian Inc. is developing a regenerative platform around GDF11 to treat age-related diseases, including Alzheimer's disease. The company, which emerged from stealth on Sept. 6, aims to modulate the protein’s pathway with antibodies, small molecules, or recombinant versions of the protein itself.

GDF11, part of the transforming growth factor β (TGFβ) family, affects cellular growth and development; and GDF deficiency in mice causes developmental abnormalities, such as agenesis of the kidneys and perinatal lethality. ...